Molecular mechanism of HIF-1-independent VEGF expression in a hepatocellular carcinoma cell line

International Journal of Molecular Medicine

Volumn 28, Issue 3, 2011, Pages 449-454

  Choi, Sae Byeol ^a   Park, Jong Bae ^b   Song, Tae Jin ^a   Choi, Sang Yong ^a  

^a Korea University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Angiogenesis; Hep3B cell line; Hepatocellular carcinoma; Hypoxia inducible factor 1; SP1; Vascular endothelial growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRANSCRIPTION FACTOR SP1; VASCULOTROPIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL CULTURE; CELL HYPOXIA; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SUPERNATANT; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959968571     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.719     Document Type: Article

References (37)

1. Harris AL: Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
2. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
3. Harada H, Kizaka-Kondoh S, Li G, et al: Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26: 7508-7516, 2007. (Pubitemid 350207705)
4. Pang RW and Poon RT: From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 (Suppl 1): 30-44, 2007. (Pubitemid 350256663)
5. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
6. Kim KR, Moon HE and Kim KW: Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med 80: 703-714, 2002.
7. Gasparini G, Longo R, Toi M and Ferrara N: Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562-577, 2005. (Pubitemid 41721816)
8. Miyoshi A, Kitajima Y, Ide T, et al: Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1α-independent manner. Int J Oncol 29: 1533-1539, 2006.
9. Levy AP, Levy NS and Goldberg MA: Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 271: 2746-2753, 1996. (Pubitemid 26047892)
10. Ryan HE, Lo J and Johnson RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998. (Pubitemid 28254373)
11. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD and Maity A: EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 66: 3197-3204, 2006.
12. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000.
13. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC and Conaway JW: Activation of HIF1 alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430-10435, 2000.
14. Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I and Montuenga L: Targeting hypoxia and angiogenesis through HIF-1alpha inhibition. Cancer Biol Ther 4: 1055-1062, 2005. (Pubitemid 41598557)
15. Semenza GL: HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88: 1474-1480, 2000.
16. Gordan JD and Simon MC: Hypoxia-inducible factors: central regulators of the tumor phenotype. Curr Opin Genet Dev 17: 71-77, 2007. (Pubitemid 46109295)
17. Mise M, Arii S, Higashituji H, et al: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23: 455-464, 1996. (Pubitemid 26087158)
18. von Marschall Z, Cramer T, Hocker M, Finkenzeller G, Wiedenmann B and Rosewicz S: Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut 48: 87-96, 2001. (Pubitemid 32042647)
19. Poon RT, Ng IO, Lau C, et al: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 233: 227-235, 2001. (Pubitemid 32106077)
20. Chao Y, Li CP, Chau GY, et al: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10: 355-362, 2003. (Pubitemid 40486931)
21. Maltepe E, Schmidt JV, Baunoch D, Bradfield CA and Simon MC: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT Nature 386: 403-407, 1997.
22. Keith B, Adelman DM and Simon MC: Targeted mutation of the murine arylhydrocarbon receptor nuclear translocator 2 (Arnt2) gene reveals partial redundancy with Arnt. Proc Natl Acad Sci USA 98: 6692-6697, 2001. (Pubitemid 32538278)
23. Ding L, Chen XP and Wang HP: Expression and clinical significance of HIF-1α protein in hepatocellular carcinoma tissues. Zhonghua Gan Zang Bing Za Zhi 12: 656-659, 2004 (In Chinese).
24. Huang GW, Yang LY and Lu WQ: Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol 11: 1705-1708, 2005.
25. Wagner K, Peters M, Scholz A, et al: Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology 126: 1828-1843, 2004.
26. Mizukami Y, Li J, Zhang X, Zimmer MA, Iliopoulos O and Chung DC: Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64: 1765-1772, 2004. (Pubitemid 38428700)
27. Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD and Maity A: Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4 471-479, 2006. (Pubitemid 44197042)
28. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G and Stokoe D: Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8: 1195-1198, 1998. (Pubitemid 28494720)
29. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999. (Pubitemid 29190320)
30. Yamada KM and Araki M: Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 114: 2375-2382, 2001. (Pubitemid 32684793)
31. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001.
32. Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H and Simons JW: Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9: 2416-2425, 2003. (Pubitemid 36842080)
33. Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor lalpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000. (Pubitemid 30183422)
34. Kaluz S, Kaluzova M and Stanbridge EJ: Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res 63: 917-922, 2003.
35. Alvarez-Tejado M, Alfranca A, Aragones J, Vara A, Landazuri MO and del Peso L: Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 277: 13508-13517, 2002. (Pubitemid 34967948)
36. Arsham AM, Plas DR, Thompson CB and Simon MC: Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem 277: 15162-15170, 2002. (Pubitemid 34952595)
37. Kang HT, Ju JW, Cho JW and Hwang ES: Down-regulation of Sp1 activity through modulation of O-glycosylation by treatment with a low glucose mimetic, 2-deoxyglucose. J Biol Chem 278: 51223-51231, 2003. (Pubitemid 38020359)